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Given these circumstances, we obtained FDA authorization under the Emergency 78
Investigational New Drug program (EIND #107,161) and from our Human Research Committee 79 to treat the patient with oral isavuconazole, which was started in November 2009. The patient 80 received a two-day oral loading dose of 200mg three times per day (600mg/day) followed by a 81 daily dose of 200mg/day, the same dose regimen being studied in the Phase 3 program. The 82 patient was able to go home two days later. 83
Four days later, the patient returned for a scheduled follow-up appointment. He 84 experienced intermittent nausea. The cutaneous lesions remained stable. He displayed mild 85 aphasia and decreased breath sounds on the right base with occasional crackles in the left base. 86
Isavuconazole (BAL4815) plasma levels were measured during the loading dose and on 87 subsequent clinic visits (Table 1) , using analytical methods based on liquid chromatography-88 mass spectrometry with a lower limit of quantification of 5ng/mL (Inovalab AG, Switzerland). 89
The trough levels were initially below the 1000-2000 ng/mL selected target range. As a result a 90 re-loading protocol of 6 doses over 48 hours was prescribed, while maintenance dose was 91 increased from 200 to 400 mg/day. Despite mild nausea and minimal elevations of alanine 92 transaminase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase, no other 93 adverse effects were noted. Since the patient had reached an isavuconazole level within the target 94 range (1322 ng/mL) before the re-loading doses, the maintenance dose was reduced back to 95 200mg/day after drug level results became available. No electrocardiogram abnormalities were 96 noted; QTc remained less than 450msec throughout treatment. 97
On his one-month follow up, neurological deficits and cutaneous lesions had resolved 98 clinically. The patient had increased appetite and gained weight. antifungal treatment is critical for optimal outcomes (3, 5) . 124
In the present case, the patient presented with disseminated mucormycosis involving 125 lung, brain and skin and was successfully treated with isavuconazole in the setting of relapsed 126 leukemia after allogeneic HSCT after failing posaconazole and being intolerant to amphotericin. 127
The diagnosis was established by skin biopsy, and imaging was consistent with lung and brain 128 involvement. Even though respiratory and skin biopsy cultures were negative, tissue PCR and 129 sequencing confirmed Rhizomucor pusillus/miehei as the causative agent (1, 2). Isavuconazole is an investigational broad-spectrum antifungal drug with in vitro and in 147 vivo activity against a broad range of yeasts and molds as well as in vitro activity against 148
Mucorales (10-12). Although our patient was treated with oral isavuconazole, the drug is also 149 being developed for intravenous administration. Both formulations of isavuconazole consist of a 150 water-soluble pro-drug (isavuconazonium, BAL-8557) that is rapidly converted to isavuconazole 151 (BAL-4815) in plasma. Similar to other triazoles, it acts by inhibiting the fungal CYP system. 152
Isavuconazole has favorable, linear pharmacokinetics and a long half-life that allows for once-153 daily administration. Intravenous isavuconazole does not require potentially-nephrotoxic 154 coadministration of cyclodextrin, which allows isavuconazole to be dosed in patients with renal 155 impairment. Furthermore, isavuconazole can be administered orally with minimal variability in 156 its bioavailability that is not influenced by food intake (13). Our patient's isavuconazole levels 157 were lower than initially targeted on the first week of treatment. This led us to reload the patient 158 and use higher isavuconazole doses transiently, but 200mg/day of isavuconazole maintenance 159 treatment was sufficient to keep plasma levels above 1000 ng/mL, which remained stable over 160 several months of periodic monitoring, similarly as to what Ervens and colleagues observed (6) . 161
The use of isavuconazole allowed the patient to go home with oral treatment. 162
Remarkably, his mucormycosis disease improved steadily with a decrease in the size of lung 163 (50%) and brain (25%) lesions, and resolution of skin lesions and brain edema, despite ongoing 164 AML relapse requiring further treatment with hydroxyurea, sorafenib and azacitidine. 
